Articolul precedent |
Articolul urmator |
367 0 |
SM ISO690:2012 MUSTEAŢĂ, Vasile, STRATAN, Valentina, CATRINICI, Larisa, VINOGRADOV, Igor, MUSTEAŢĂ, Larisa, DUDNIC, Cristina. Management of elderly patients with chronic myeloproliferative hemopathies – actual issue of internal medicine and public health. In: Congresul consacrat aniversării a 75-a de la fondarea Universității de Stat de Medicină şi Farmacie „Nicolae Testemiţanu”, 21-23 octombrie 2020, Chişinău. Chişinău: USMF, 2020, p. 243. |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
Congresul consacrat aniversării a 75-a de la fondarea Universității de Stat de Medicină şi Farmacie „Nicolae Testemiţanu” 2020 | |||||
Congresul "Congresul consacrat aniversării a 75-a de la fondarea Universității de Stat de Medicină şi Farmacie „Nicolae Testemiţanu”" Chişinău, Moldova, 21-23 octombrie 2020 | |||||
|
|||||
Pag. 243-243 | |||||
|
|||||
Descarcă PDF | |||||
Rezumat | |||||
Background. Chronic myeloproliferative hemopathies (CMH) as a whole are the most common chronic leukemias in the elderlies within the structure of morbidity by hematological malignancies, and in advanced stages they are characterized by a severe evolution and negative socio-economic impact. Objective of the study. Diagnosis identification and evaluation of management of CMH. Material and Methods. The study enrolled 78 elderly patients: 19 (24,4%) with idiopathic myelofibrosis (IMF), 28 (35,9%) with chronic myeloid leukemia (CML), 31 (39,7%) with polycythemia vera (PV), who were followed up and treated at the Institute of Oncology in the period 1995–2019. The commonly used research methods were: morphologic, molecular, epidemiological, decsriptive, clinicoanalytical, cohort statistics. Results. Overall survival in patients aged ≥ 60 treated with TKI over 1 and 5 years was 95 and 39%, being lower as compared with the same indices in the totality of CML. In elderly PV patients the overall survival over 5 and 10 years constituted 93.5% and 76.4%, being lesser than registered in all patients with PV. Although the relapse rate was lower in patients treated with busulfan as compared to those managed with hydroxycarbamide, the was no difference of the survival of the elderlies undergoing chemotherapy with these antineoplastic agents. The rate of hematological remissions and survival under the busulfan and hydroxycarbamide therapy in patients with MFI were lower than in PV. Conclusion. No difference in long-term outcomes of PV treatment with busulfan and hydroxycarbamide combined with phlebotomies was revealed in elderly patients, those in IMF being lesser. The survival in elderlies decays due to the development of vascular accidents on the account of leuko-, thrombocytosis. |
|||||
Cuvinte-cheie chronic myeloproliferative hemopathies, Diagnosis, management, hemopatiile mieloproliferative cronice, diagnostic, management |
|||||
|